Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Grunenthal GmbH - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2016', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Grunenthal GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Grunenthal GmbH - The report provides overview of Grunenthal GmbH including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Grunenthal GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Grunenthal GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Grunenthal GmbH - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Grunenthal GmbH's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Grunenthal GmbH Snapshot 5 Grunenthal GmbH Overview 5 Key Information 5 Key Facts 5 Grunenthal GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 Grunenthal GmbH - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Grunenthal GmbH - Pipeline Products Glance 13 Grunenthal GmbH - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Grunenthal GmbH - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Grunenthal GmbH - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Grunenthal GmbH - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 Grunenthal GmbH - Drug Profiles 19 cebranopadol 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 tapentadol hydrochloride 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecule 1 for Pain 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule 2 for Pain 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GRTTA-2210 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 RO-656570 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule 3 for Pain 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Activate KCNQ and TSPO for Pain 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Grunenthal GmbH - Pipeline Analysis 32 Grunenthal GmbH - Pipeline Products by Target 32 Grunenthal GmbH - Pipeline Products by Route of Administration 34 Grunenthal GmbH - Pipeline Products by Molecule Type 35 Grunenthal GmbH - Pipeline Products by Mechanism of Action 36 Grunenthal GmbH - Recent Pipeline Updates 38 Grunenthal GmbH - Dormant Projects 40 Grunenthal GmbH - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 axomadol 41 lexanopadol 41 Grunenthal GmbH - Company Statement 42 Grunenthal GmbH - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Grunenthal GmbH, Key Information 5 Grunenthal GmbH, Key Facts 5 Grunenthal GmbH - Pipeline by Indication, 2016 7 Grunenthal GmbH - Pipeline by Stage of Development, 2016 9 Grunenthal GmbH - Monotherapy Products in Pipeline, 2016 10 Grunenthal GmbH - Partnered Products in Pipeline, 2016 11 Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2016 12 Grunenthal GmbH - Phase III, 2016 13 Grunenthal GmbH - Phase II, 2016 14 Grunenthal GmbH - Phase I, 2016 15 Grunenthal GmbH - Preclinical, 2016 16 Grunenthal GmbH - Discovery, 2016 17 Grunenthal GmbH - Unknown, 2016 18 Grunenthal GmbH - Pipeline by Target, 2016 33 Grunenthal GmbH - Pipeline by Route of Administration, 2016 34 Grunenthal GmbH - Pipeline by Molecule Type, 2016 35 Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2016 37 Grunenthal GmbH - Recent Pipeline Updates, 2016 38 Grunenthal GmbH - Dormant Developmental Projects,2016 40 Grunenthal GmbH - Discontinued Pipeline Products, 2016 41 Grunenthal GmbH, Other Locations 43 Grunenthal GmbH, Subsidiaries 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.